Vinay Prasad oversees vaccines, gene therapies and the blood supply. His views raise alarms for pharmaceutical companies and ...

While Prasad’s views may not align with many of the FDA’s traditional policies, they do fit into a broader MAHA agenda of ...

Tucked inside President Trump's executive order on drug pricing is a sentence that appears to threaten the FDA could yank ...

UnitedHealth Group CEO Andrew Witty abruptly stepped down from the health insurance and care conglomerate on Tuesday, citing ...

Hospitals pay provider taxes, helping states spend more on Medicaid and increase the amounts paid by the federal government.

This is a hectic week, and it got off to an early start with President Trump on Sunday evening breaking the embargo on his ...

Biotech investment firm RA Capital has laid off staff at its internal startup incubator, highlighting the instability among ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

US president Donald Trump has announced an executive order aimed at reducing US prescription drug costs by 30-80%. The policy would align US drug prices with the lowest prices paid internationally and ...

The SEQUOIA-HCM data suggests that the company is on track to bring aficamten to market as a rival to Bristol-Myers Squibb’s Camzyos (mavacamten), which is currently the only FDA-approved ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

Gabe Whisnant is a Breaking News Editor at Newsweek based in North Carolina. Prior to joining Newsweek in 2023, he directed daily publications in North and South Carolina. As an executive editor ...